Kevin Feeley Sells 402 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 402 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the transaction, the chief financial officer now directly owns 5,044 shares in the company, valued at $454,212.20. This represents a 7.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total value of $362,565.79.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total transaction of $108,737.20.

GeneDx Stock Down 4.1 %

Shares of NASDAQ:WGS traded down $4.01 during mid-day trading on Monday, hitting $94.46. 668,407 shares of the company traded hands, compared to its average volume of 612,654. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The stock has a 50-day moving average price of $84.69 and a two-hundred day moving average price of $70.37. GeneDx Holdings Corp. has a 12-month low of $7.72 and a 12-month high of $115.60. The stock has a market cap of $2.65 billion, a P/E ratio of -48.19 and a beta of 1.91.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The company had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. On average, equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on WGS. The Goldman Sachs Group upped their price target on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen upped their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $72.33.

Hedge Funds Weigh In On GeneDx

Several institutional investors have recently modified their holdings of the business. Barclays PLC boosted its position in GeneDx by 346.3% in the third quarter. Barclays PLC now owns 18,921 shares of the company’s stock worth $803,000 after purchasing an additional 14,681 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of GeneDx during the 3rd quarter worth $325,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of GeneDx by 304.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock worth $6,240,000 after buying an additional 110,666 shares during the last quarter. Franklin Resources Inc. bought a new position in GeneDx during the third quarter valued at about $301,000. Finally, Principal Financial Group Inc. purchased a new stake in GeneDx during the third quarter worth about $604,000. 61.72% of the stock is owned by institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.